Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
White Paper
A Digital Future for Value Added Medicines: Supporting Positive Patient Behaviour
Sep 23, 2019
  • Library
  • Digital Future for Value Added Medicines
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

In the haste to focus on the latest technological advance for increasingly tiny patient populations, something's been lost by the pharmaceutical industry - the desire to improve treatments for the many millions of patients who take mainstream, older medications. This is where value added medicines, one of the rising sources of industry innovation and value growth, comes in.

In this paper, we analyse the drivers behind the sector, its challenges and what the future holds for value added medicines.

GENERICS:
A SECTOR UNDER PRESSURE

BACKGROUND

Over the past five years, global generics volume has decelerated, and not only in developed markets but for emerging economies as well. The projected 3% of future global generics growth is only marginally faster than growth driven by the shifts in demographics alone.

Recent small molecule loss of exclusivity (LOE) events have generally had lower peak sales and lower volumes than those seen in 2012, when atorvastatin’s patent expired. As innovation specialises and moves definitively away from massmarket small molecules, the business model for traditional generics manufacturers has to change. The generic pipe has changed, and the emerging market opportunities are not as strong as they could be.

Moreover, this innovation shift means that the majority of treated patients, those taking generic medicines, are not benefitting from potential improvements to their therapies due to a lack of incentives to innovate in major therapy areas which are largely generic, like hypertension, depression, or pain.

In developed countries, a greater number of manufacturers in the market, payer consolidation and a focus on cost containment have driven prices down. This is especially problematic as the US has long been seen as a principal source of return on investment.

In emerging economies, the dynamics are similar. Intense competition, cost-reduction policies and a saturation of generics usage has slowed down volume growth in recent years. This trend does not look like it will slow anytime soon as payer mechanisms, such as China’s volume-based purchasing, are set to expand.

This leaves generics manufacturers stuck between a rock and a hard place. Traditionally they have sought growth by moving into new markets to seek volume expansion or refreshing their portfolio to be first movers in new LOE opportunities. The reality is that increased competition, payer pressure and sluggish volume has meant troubled companies are discarding assets, primarily from large western companies to eastern ones able to operate at a lower cost base, such as Aurobindo’s acquisition of US dermatology from Sandoz.


UNMET NEEDS

Globally, four of every five medicines consumed in 2017 were generics. As generics of the current standard of care become available, cost-conscious payers tend to adopt a ‘good enough’ mindset, where budgetary concerns drive procurement of the least costly product. This can, however, be a false economy.

Patients value greater convenience when taking their medicines. Increasing administration convenience is a large factor in addressing adherence, a major source of healthcare inefficiency. For example, a 2012 meta-analysis2 on avoidable costs from suboptimal medical use showed that non-adherence contributed $105bn (57% of total avoidable costs, $269bn) in the US alone.

The potential of these medicines are not limited to adherence. Improvements in other metrics such as safety and tolerability also offer opportunities to enhance caregiving using smarter therapy design.

If companies wish to compete effectively in the small molecule market, they need to change their business models to address the opportunities brought by unmet needs that remain.


DOWNLOAD TO LEARN MORE

Related solutions

Contact Us